se gb

Gunilla Lundmark appointed as new CEO for Dilanest

STOCKHOLM, October 25 2010. Gunilla Lundmark has been appointed new CEO for Dilanest AB, a Karolinska Development portfolio company. She is currently Vice President at Q-Med, and will assume the position in January, 2011. Gunilla succeeds Anders Åsell who has decided to leave the company to assume the role as General Manager for Grifols in the Nordic countries.

“We are very pleased with the recruitment of Gunilla Lundmark as new CEO. Gunilla has vast experience from research, development and marketing of pharmaceuticals and medical devices and will be a valuable contribution to the company. At the same time we thank Anders Åsell for his valuable work at Dilanest since the company was founded in 2009”, says Bengt Å Johansson, Chairman of the board of Dilanest.

Gunilla Lundmark has vast experience from the pharmaceutical industry, including as General Manager of Q-Med Australia, with responsibilities for Australia and New Zealand. She is currently Vice President and Head of Operations at Q-Med.

For further information, please contact:
Bengt Å Johansson, Chairman of the Board, Dilanest AB
Telephone: +46 706 80 47 62, e-mail: bengt.johansson@dilafor.com

Gunilla Lundmark, appointed CEO, Dilanest AB
Telephone: +46 709 74 90 57, e-mail gunilla.lundmark@dilanest.com

About Dilanest
Dilanest develops unique formulations for topical anesthesia in gynecology and obstetrics. The company will commence safety studies for its first Candidate Drug during fourth quarter 2010, with the ambition to initiate first trials in man during 2011. Dilanest was founded in 2009 as a result from preclinical studies of the changes in human uterine innervation during pregnancy at Karolinska Institutet.

2010-10-25